Evidence map›Paper›PMID 42096152›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Nanoluciferase-Based Reporters for Clostridioides difficile.

Jeroen Corver, Ana M Oliveira Paiva, Wiep Klaas Smits

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeroen CorverLeiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Ana M Oliveira PaivaLeiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Wiep Klaas SmitsLeiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. w.k.smits@lumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoluciferase (NanoLuc®) is a small, bright reporter enzyme known for its versatility. Detection of nanoluciferase, dependent on the substrate furimazine, is highly sensitive and can be adapted to multiple cellular assays. This chapter describes the use of codon-optimized nanoluciferase as a reporter for promoter activity, to assess protein topology and to investigate protein-protein interactions in Clostridioides difficile.

Indexed as

Clostridioides difficileGenes, ReporterLuciferasesBacterial ProteinsPromoter Regions, GeneticBacterial ProteinsLuciferasesGene expressionLuciferaseReporter gene assay

Identifiers

PMID42096152

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.